Business Context and Reporting Period
Company: Spero Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 19, 2022
Event: Exercise of a contract option by the Biomedical Advanced Research and Development Authority (BARDA).
Key Financial Metrics
This filing reports specific contract funding updates rather than general financial performance metrics (revenue, profit, cash flow, or margins) for a reporting period.
- Committed Funding Increase: $12.9 million (new option exercised).
- Total Committed Funding: $46.9 million.
- Total Potential Contract Value (BARDA): $59.7 million.
- Additional DTRA Funding: Up to approximately $10.0 million for nonclinical biodefense aspects of tebipenem HBr.
Material Changes
The primary material change is the expansion of the 2018 contract with BARDA. The exercise of the new option increases committed funding by $12.9 million. This funding is designated to support a clinical trial and related activities for orally administered tebipenem pivoxil for treating pediatric patients with complicated urinary tract infections, including acute pyelonephritis.
Outlook and Management Commentary
Management indicates that the additional $12.9 million will directly support clinical trial activities. The filing notes the continued collaboration with the Defense Threat Reduction Agency (DTRA) for nonclinical biodefense aspects of the program. No specific financial guidance, risk factors, or contingencies beyond the scope of the contract exercise were detailed in this specific 8-K text.
Key Facts for Investor Verification
- Verify the timeline for the commencement of the clinical trial for pediatric urinary tract infections.
- Confirm the specific milestones required to unlock the remaining potential contract value up to $59.7 million.
- Review the terms of the DTRA collaboration regarding the $10.0 million for nonclinical biodefense aspects.
- Assess the impact of this funding on the company's cash runway and future capital requirements.